TABLE 2

Outcomes associated with the combination of vancomycin and beta-lactamsa

Patient
characteristic or
outcome
Value(s)
VPT
(n = 366)
VC
(n= 1,734)
PbVPT
(n = 366)
VM
(n = 392)
Pb
No. (%) with any AKI144 (39.3)419 (24.2)<0.0001144 (39.3)92 (23.5)<0.0001
No. (%) with stage 2 AKI55 (15.0)101 (5.8)<0.000155 (15.0)26 (6.6)<0.0001
No. (%) with stage 3 AKI24 (6.6)31 (1.8)<0.000124 (6.6)5 (1.3)<0.0001
No. (%) with RRT4 (1.1)21 (1.2)1.0004 (1.1)6 (1.5)0.754
Day of AKI occurrence3.2 ± 2.62.6 ± 2.50.0303.2 ± 2.62.2 ± 2.10.003
ICU LOS, h [IQR]82.5 [46.74–151.0]94.0 [46.0–214.5]<0.000182.5 [46.74–151.0]94.0 [53.0–210.75]0.001
ICU LOS – AKI subgroup LOS93 [51–168]107 [58–223]0.01393 [51–168]110 [60–220]0.058
Hospital LOS, days [IQR]9.0 [6.0–17.0]9.0 [5.0–16.0]0.5589.0 [6.0–17.0]10.0 [6–17.75]0.236
No. (%) with hospital mortality42 (11.5)265 (15.3)0.06142 (11.5)67 (17.1)0.028
No. (%) with hospital mortality –no. (%) in AKI subgroup25 (17.4)111 (26.4)0.01825 (17.4)26 (28.3)0.057
  • a Abbreviations: AKI, acute kidney injury; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; OR, odds ratio; RRT, renal replacement therapy; VC, vancomycin plus cefepime; VM, vancomycin plus meropenem; VPT, vancomycin plus piperacillin-tazobactam.

  • b P values are shown for comparisons made separately between VPT and VC (OR [95% CI], 2.04 [1.61 to 2.58]) and between VPT and VM (OR, 2.12 [1.61 to 2.90]). Unadjusted bivariate odds ratio values represent the primary outcome for any AKI. Comparisons were made separately between VPT and VC and between VPT and VM.